https://scholars.lib.ntu.edu.tw/handle/123456789/636487
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Peng, Shang-Hsuan | en_US |
dc.contributor.author | CHING-HUNG LIN | en_US |
dc.contributor.author | I-CHUN CHEN | en_US |
dc.contributor.author | YING-CHUN SHEN | en_US |
dc.contributor.author | DWANG-YING CHANG | en_US |
dc.contributor.author | WEI-WU CHEN | en_US |
dc.contributor.author | Huang, Shu-Min | en_US |
dc.contributor.author | Hu, Fu-Chang | en_US |
dc.contributor.author | YEN-SHEN LU | en_US |
dc.date.accessioned | 2023-10-25T02:41:45Z | - |
dc.date.available | 2023-10-25T02:41:45Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/636487 | - |
dc.description.abstract | Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Cancer medicine | en_US |
dc.subject | Asian; advanced cancers; meta-analysis; overall survival; pembrolizumab | en_US |
dc.title | Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/cam4.6563 | - |
dc.identifier.pmid | 37737544 | - |
dc.identifier.scopus | 2-s2.0-85171731862 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85171731862 | - |
dc.relation.journalvolume | 12 | en_US |
dc.relation.journalissue | 19 | en_US |
dc.relation.pageend | 20051 | en_US |
item.languageiso639-1 | en | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Clinical Trial Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.orcid | 0000-0003-2403-4056 | - |
crisitem.author.orcid | 0000-0003-4112-4029 | - |
crisitem.author.orcid | 0000-0001-7461-1291 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。